Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.

Kitchin N, Remich SA, Peterson J, Peng Y, Gruber WC, Jansen KU, Pride MW, Anderson AS, Knirsch C, Webber C.

Clin Infect Dis. 2019 May 24. pii: ciz153. doi: 10.1093/cid/ciz153. [Epub ahead of print]

PMID:
31125055
2.

A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults.

Inoue M, Yonemura T, de Solom R, Yamaji M, Aizawa M, Knirsch C, Pride MW, Jansen KU, Gruber W, Webber C.

Vaccine. 2019 May 1;37(19):2600-2607. doi: 10.1016/j.vaccine.2019.03.014. Epub 2019 Apr 5.

PMID:
30962095
3.

A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.

Buurman ET, Timofeyeva Y, Gu J, Kim JH, Kodali S, Liu Y, Mininni T, Moghazeh S, Pavliakova D, Singer C, Singh S, Handke LD, Lotvin J, Prasad AK, Scully IL, Donald RGK, Jansen KU, Anderson AS.

J Infect Dis. 2019 Jun 5;220(1):105-115. doi: 10.1093/infdis/jiz062.

4.

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.

Vesikari T, Østergaard L, Beeslaar J, Absalon J, Eiden JJ, Jansen KU, Jones TR, Harris SL, Maansson R, Munson S, O'Neill RE, York LJ, Perez JL.

Vaccine. 2019 Mar 14;37(12):1710-1719. doi: 10.1016/j.vaccine.2018.11.073. Epub 2019 Feb 12.

PMID:
30770221
5.

Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States.

Mohamed N, Timofeyeva Y, Jamrozy D, Rojas E, Hao L, Silmon de Monerri NC, Hawkins J, Singh G, Cai B, Liberator P, Sebastian S, Donald RGK, Scully IL, Jones CH, Creech CB, Thomsen I, Parkhill J, Peacock SJ, Jansen KU, Holden MTG, Anderson AS.

PLoS One. 2019 Jan 14;14(1):e0208356. doi: 10.1371/journal.pone.0208356. eCollection 2019.

6.

A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec.

Gilca R, De Wals P, Nolan SM, Kitchin N, Eiden JJ, Jiang Q, Jones CH, Jansen KU, Anderson AS, Pedneault L.

mSphere. 2018 Dec 5;3(6). pii: e00427-18. doi: 10.1128/mSphere.00427-18.

7.

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.

Thompson AR, Klein NP, Downey HJ, Patterson S, Sundaraiyer V, Watson W, Clarke K, Jansen KU, Sebastian S, Gruber WC, Scott DA, Schmöele-Thoma B.

Hum Vaccin Immunother. 2019;15(2):444-451. doi: 10.1080/21645515.2018.1533777. Epub 2018 Oct 25.

8.

The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery.

Gurtman A, Begier E, Mohamed N, Baber J, Sabharwal C, Haupt RM, Edwards H, Cooper D, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2019;15(2):358-370. doi: 10.1080/21645515.2018.1523093. Epub 2018 Sep 27.

PMID:
30215582
9.

Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response.

Dupont CD, Scully IL, Zimnisky RM, Monian B, Rossitto CP, O'Connell EB, Jansen KU, Anderson AS, Love JC.

mSphere. 2018 Aug 22;3(4). pii: e00217-18. doi: 10.1128/mSphere.00217-18.

10.

Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides.

Pavliakova D, Giardina PC, Moghazeh S, Sebastian S, Koster M, Pavliak V, McKeen A, French R, Jansen KU, Pride M.

mSphere. 2018 Aug 8;3(4). pii: e00128-18. doi: 10.1128/mSphere.00128-18.

11.

Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.

Tan CY, Immermann FW, Sebastian S, Pride MW, Pavliakova D, Belanger KA, Watson W, Scott DA, Sidhu M, Jansen KU, Giardina PC.

mSphere. 2018 Aug 8;3(4). pii: e00127-18. doi: 10.1128/mSphere.00127-18.

12.

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults.

Inoue M, Yonemura T, Baber J, Shoji Y, Aizawa M, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Hum Vaccin Immunother. 2018;14(11):2682-2691. doi: 10.1080/21645515.2018.1496764. Epub 2018 Aug 17.

13.

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.

Perez JL, Absalon J, Beeslaar J, Balmer P, Jansen KU, Jones TR, Harris S, York LJ, Jiang Q, Radley D, Anderson AS, Crowther G, Eiden JJ.

Expert Rev Vaccines. 2018 Jun;17(6):461-477. doi: 10.1080/14760584.2018.1483726. Epub 2018 Jun 22. Review.

PMID:
29883226
14.

The role of vaccines in fighting antimicrobial resistance (AMR).

Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2018;14(9):2142-2149. doi: 10.1080/21645515.2018.1476814. Epub 2018 Jul 9. Review.

15.

Vaccination strategies for the prevention of meningococcal disease.

Vuocolo S, Balmer P, Gruber WC, Jansen KU, Anderson AS, Perez JL, York LJ.

Hum Vaccin Immunother. 2018 May 4;14(5):1203-1215. doi: 10.1080/21645515.2018.1451287. Epub 2018 Apr 13. Review.

16.

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.

McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL, Jones TR, Li S, Zlotnick G, Vogel U, Claus H, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Wang X, Vuong J, Mayer LW, Pride MW, Jansen KU, Anderson AS.

MBio. 2018 Mar 13;9(2). pii: e00036-18. doi: 10.1128/mBio.00036-18.

17.

The role of vaccines in preventing bacterial antimicrobial resistance.

Jansen KU, Knirsch C, Anderson AS.

Nat Med. 2018 Jan 9;24(1):10-19. doi: 10.1038/nm.4465. Review.

PMID:
29315295
18.

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.

Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Prégaldien JL, Ginis J, Staerke NB, Perez JL; B1971009 and B1971016 Trial Investigators.

N Engl J Med. 2017 Dec 14;377(24):2349-2362. doi: 10.1056/NEJMoa1614474.

19.

Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay.

Pride MW, Jansen KU.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00239-17. doi: 10.1128/CVI.00239-17. Print 2017 Nov. No abstract available.

20.

Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study.

Scully IL, McNeil LK, Pathirana S, Singer CL, Liu Y, Mullen S, Girgenti D, Gurtman A, Pride MW, Jansen KU, Huang PL, Anderson AS.

Diabetol Metab Syndr. 2017 Oct 3;9:76. doi: 10.1186/s13098-017-0276-3. eCollection 2017.

21.

Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B.

Gribenko A, Severina E, Sidhu MK, Jansen KU, Green BA, Matsuka YV.

Biochem Biophys Rep. 2017 Jan 5;9:193-202. doi: 10.1016/j.bbrep.2016.12.015. eCollection 2017 Mar.

22.

Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen specific memory B cell repertoires.

Jia B, McNeil LK, Dupont CD, Tsioris K, Barry RM, Scully IL, Ogunniyi AO, Gonzalez C, Pride MW, Gierahn TM, Liberator PA, Jansen KU, Love JC.

PLoS One. 2017 Sep 14;12(9):e0183738. doi: 10.1371/journal.pone.0183738. eCollection 2017.

23.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial.

Idoko OT, Mboizi RB, Okoye M, Laudat F, Ceesay B, Liang JZ, Le Dren-Narayanin N, Jansen KU, Gurtman A, Center KJ, Scott DA, Kampmann B, Roca A.

Vaccine. 2017 May 31;35(24):3256-3263. doi: 10.1016/j.vaccine.2017.04.049. Epub 2017 May 4.

24.

Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.

Taha MK, Hawkins JC, Liberator P, Deghmane AE, Andrew L, Hao L, Jones TR, McNeil LK, O'Neill RE, Perez JL, Jansen KU, Anderson AS.

Vaccine. 2017 Mar 13;35(11):1530-1537. doi: 10.1016/j.vaccine.2017.01.066. Epub 2017 Feb 10.

PMID:
28196734
25.

Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study.

van Ravenhorst MB, Bijlsma MW, van Houten MA, Struben VMD, Anderson AS, Eiden J, Hao L, Jansen KU, Jones H, Kitchin N, Pedneault L, Sanders EAM, van der Ende A.

Clin Microbiol Infect. 2017 Aug;23(8):573.e1-573.e7. doi: 10.1016/j.cmi.2017.02.008. Epub 2017 Feb 10.

26.

SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.

Begier E, Seiden DJ, Patton M, Zito E, Severs J, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Vaccine. 2017 Feb 22;35(8):1132-1139. doi: 10.1016/j.vaccine.2017.01.024. Epub 2017 Jan 28.

PMID:
28143674
27.

Vaccine development to prevent Staphylococcus aureus surgical-site infections.

Mohamed N, Wang MY, Le Huec JC, Liljenqvist U, Scully IL, Baber J, Begier E, Jansen KU, Gurtman A, Anderson AS.

Br J Surg. 2017 Jan;104(2):e41-e54. doi: 10.1002/bjs.10454. Review.

PMID:
28121039
28.

Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Review.

29.

Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.

Frenck RW Jr, Creech CB, Sheldon EA, Seiden DJ, Kankam MK, Baber J, Zito E, Hubler R, Eiden J, Severs JM, Sebastian S, Nanra J, Jansen KU, Gruber WC, Anderson AS, Girgenti D.

Vaccine. 2017 Jan 5;35(2):375-384. doi: 10.1016/j.vaccine.2016.11.010. Epub 2016 Dec 1.

30.

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

Creech CB, Frenck RW Jr, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J.

Vaccine. 2017 Jan 5;35(2):385-394. doi: 10.1016/j.vaccine.2016.11.032. Epub 2016 Nov 17.

31.

Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected Adults.

Albrich WC, Pride MW, Madhi SA, Callahan J, Adrian PV, French R, van Niekerk N, Sebastian S, Souza V, Telles JN, Paranhos-Baccalà G, Jansen KU, Klugman KP.

J Clin Microbiol. 2016 Dec 28;55(1):302-312. doi: 10.1128/JCM.01573-16. Print 2017 Jan.

32.

Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.

Harris SL, Donald RG, Hawkins JC, Tan C, O'Neill R, McNeil LK, Perez JL, Anderson AS, Jansen KU, Jones TR.

Pediatr Infect Dis J. 2017 Feb;36(2):216-223. doi: 10.1097/INF.0000000000001399.

PMID:
27846061
33.

The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease.

Luo Y, Friese OV, Runnels HA, Khandke L, Zlotnick G, Aulabaugh A, Gore T, Vidunas E, Raso SW, Novikova E, Byrne E, Schlittler M, Stano D, Dufield RL, Kumar S, Anderson AS, Jansen KU, Rouse JC.

AAPS J. 2016 Nov;18(6):1562-1575. Epub 2016 Sep 7.

PMID:
27604766
34.

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.

Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Lee SS, Perez JL; 6108A12001 Study Investigators.

Lancet Infect Dis. 2017 Jan;17(1):58-67. doi: 10.1016/S1473-3099(16)30314-0. Epub 2016 Oct 11.

PMID:
27745812
35.

Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.

Marshall H, Nissen M, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber WC, Jansen KU, Anderson AS, Zito ET, Girgenti D.

J Infect. 2016 Nov;73(5):437-454. doi: 10.1016/j.jinf.2016.08.004. Epub 2016 Aug 9.

PMID:
27519620
36.

Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.

Dayan GH, Mohamed N, Scully IL, Cooper D, Begier E, Eiden J, Jansen KU, Gurtman A, Anderson AS.

Expert Rev Vaccines. 2016 Nov;15(11):1373-1392. Epub 2016 May 9. Review.

PMID:
27118628
37.

Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.

Green LR, Eiden J, Hao L, Jones T, Perez J, McNeil LK, Jansen KU, Anderson AS.

Methods Mol Biol. 2016;1403:445-69. doi: 10.1007/978-1-4939-3387-7_25.

PMID:
27076147
38.

Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution.

Clark SA, Lekshmi A, Lucidarme J, Hao L, Tsao H, Lee-Jones L, Jansen KU, Newbold LS, Anderson AS, Borrow R.

J Infect. 2016 Jul;73(1):63-70. doi: 10.1016/j.jinf.2016.03.012. Epub 2016 Mar 26.

PMID:
27025206
39.

Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine.

Bryan JT, Buckland B, Hammond J, Jansen KU.

Curr Opin Chem Biol. 2016 Jun;32:34-47. doi: 10.1016/j.cbpa.2016.03.001. Epub 2016 Mar 18. Review.

PMID:
26994695
40.

A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.

Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L.

Vaccine. 2016 Apr 19;34(18):2082-91. doi: 10.1016/j.vaccine.2016.03.010. Epub 2016 Mar 15.

PMID:
26993331
42.

Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection.

Anderson AS, Scully IL, Buurman ET, Eiden J, Jansen KU.

MBio. 2016 Mar 8;7(2):e00225. doi: 10.1128/mBio.00225-16.

43.

A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.

Ostergaard L, Lucksinger GH, Absalon J, Beeslaar J, Eiden J, Jansen KU, York LJ, Quinn A, Graversen ME, Perez JL.

Vaccine. 2016 Mar 14;34(12):1465-71. doi: 10.1016/j.vaccine.2016.01.044. Epub 2016 Feb 1.

44.

Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.

Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, Ginis J, Perez JL.

Pediatr Infect Dis J. 2016 May;35(5):548-54. doi: 10.1097/INF.0000000000001072.

PMID:
26835974
45.

Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.

Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):180-7. doi: 10.1093/jpids/piv064. Epub 2016 Jan 23.

46.

Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.

Reiner DM, Bhuyan P, Eiden JJ, Ginis J, Harris S, Jansen KU, Jiang Q, Jones TR, O'Neill RE, York LJ, Perez JL.

Vaccine. 2016 Feb 3;34(6):809-13. doi: 10.1016/j.vaccine.2015.12.016. Epub 2015 Dec 19.

PMID:
26707218
47.

Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.

Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):152-60. doi: 10.1093/jpids/piv039. Epub 2015 Aug 4.

48.

Anti-infective vaccination in the 21st century-new horizons for personal and public health.

Scully IL, Swanson K, Green L, Jansen KU, Anderson AS.

Curr Opin Microbiol. 2015 Oct;27:96-102. doi: 10.1016/j.mib.2015.07.006. Epub 2015 Sep 5. Review.

49.

Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection.

Scully IL, Timofeyeva Y, Keeney D, Matsuka YV, Severina E, McNeil LK, Nanra J, Hu G, Liberator PA, Jansen KU, Anderson AS.

Vaccine. 2015 Oct 5;33(41):5452-5457. doi: 10.1016/j.vaccine.2015.08.029. Epub 2015 Aug 28.

50.

Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Jones CH, Mohamed N, Rojas E, Andrew L, Hoyos J, Hawkins JC, McNeil LK, Jiang Q, Mayer LW, Wang X, Gilca R, De Wals P, Pedneault L, Eiden J, Jansen KU, Anderson AS.

J Clin Microbiol. 2016 Jan;54(1):25-34. doi: 10.1128/JCM.01447-15. Epub 2015 Aug 26.

Supplemental Content

Loading ...
Support Center